Free Daily Podcast Summary
The GMP Insider: Daily Summaries Delivered
by Tushar Arora
GMP Insider is your go-to podcast for practical insights into pharmaceutical quality, Good Manufacturing Practices (GMP), and regulatory compliance.Designed for quality professionals, manufacturing teams, and pharma leaders, this show breaks down complex regulations into clear, real-world guidance. Each episode explores topics like audits, CAPA, data integrity, quality systems, validation, and global regulatory expectations — all with a focus on protecting patients and building strong quality cultures.Whether you work in Quality Assurance, Quality Control, Manufacturing, or Regulatory Affairs, GMP Insider helps you stay compliant, confident, and ahead in an ever-evolving pharmaceutical industry.New episodes deliver:• GMP best practices• Audit readiness strategies• Real compliance case studies• Industry trends and updates• Expert tips from quality professionals From batch to patient — quality is everything.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 days ago15 min
Contamination Control Strategy (CCS) Under EU GMP Annex 1
Most contamination control strategies fail on page one — not because anything in them is wrong, but because everything in them is copied from somewhere else. Marcus and Priya break down the CCS under EU GMP Annex 1: what it actually has to contain, how facility design, people, sterilisation, media fills, monitoring, and disinfection connect into one risk-based argument, the five failure patterns inspectors find again and again, and how to keep the strategy alive instead of letting it become a static binder.• What a CCS is under Annex 1 — planned controls for microorganisms, particles, and pyrogens, built on ICH Q9 risk management• Start with sources, not solutions: people, materials, air, utilities, and the process itself — prevention, detection, and response for each• First air: what it is, how interventions break it, and why design and training must protect it• People, gowning, and behaviour: qualification, monitoring, and what a bad trend must trigger• Process controls: sterilisation, PUPSIT, validated material transfer, and the media fill as the strategy's exam• Monitoring and disinfection as the feedback loop: trending, alert vs action limits, and disinfectant efficacy against site flora• The five failures inspectors actually find: template strategies, static documents, missing interactions, monitoring divorced from action, and rationale gaps• Keeping the strategy alive: event-based review triggers, a named owner, and sterility metrics in front of leadershipNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.
- 4 days ago14 min
Deviation Investigation & Root Cause Analysis: 5 Whys Done Right
Most deviation investigations fail not because teams pick the wrong tool, but because they stop asking why the moment the answer becomes uncomfortable — usually at "human error" and a retraining record. Marcus and Priya walk through a real investigation: containment and timeline reconstruction in the first hours, the 5 Whys worked step by step on evidence, where the tool breaks, the fishbone breadth check, and how root cause should dictate a CAPA with an effectiveness check that can actually fail.• What a deviation is under 21 CFR 211.192 — and why investigation depth must match risk• The first hours: containment first, then timeline reconstruction from records, not memory• The 5 Whys done right: a precise problem statement, verified answers, and the system-level stopping rule• Where the 5 Whys breaks: single-lane tunnels, opinion chains, leading questions, and stopping at human error• Why human error is a starting point for questions, never a root cause• Checking the chain: fishbone categories, evidence tests, and documenting causes ruled out• From root cause to CAPA that works: extent of condition and a countable effectiveness criterion• What good investigators do differently — and why investigation quality is a leadership metricNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.
- 1 weeks ago15 min
How to Respond to an FDA 483 (and Warning Letter) in 15 Working Days
The inspection is over — and the second half of it has just started. Your written response to a Form FDA 483 is due within 15 working days, and FDA weighs it before deciding whether the matter ends there or escalates to a Warning Letter. Marcus and Priya lay out the full 15-day playbook: what a 483 is and is not, day-one triage and ownership, extent-of-condition review, root cause and CAPA discipline, evidence and timelines, the cold-read challenge review, and the five failures that sink responses again and again.• What a Form FDA 483 is — and is not: inspectional observations, not a final agency determination• The 15-working-day clock: when it starts, and why a late response can arrive after the decision• Days 1–2: one response owner, every observation logged verbatim, containment and extent-of-condition• Days 3–7: real root cause, and separating correction, corrective action, preventive action, and effectiveness checks• Days 8–15: how to structure and write the response, tone, disagreement with evidence, and the cold-read review• Warning Letters: same discipline, higher stakes — responding to the pattern, not just the paragraphs• The five failures that sink responses: narrow fixes, human-error shortcuts, promise piles, defensive tone, missed commitmentsNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.
- 1 weeks ago15 min
FDA Inspection Readiness 2026: The New Cross-System Inspection Model
FDA doesn't inspect your quality systems in silos anymore. The new inspection model is hypothesis-driven: the investigator pulls one thread — a complaint, a repeat deviation — through CAPA, risk management, and design as a single connected system, and watches whether your story holds. Marcus and Priya break down what changed in 2026, why training records and binders no longer equal readiness, the inspection playbook from war room to escorts, and the daily habits that make a site genuinely ready.• The 2026 shift: from subsystem inspections to hypothesis-driven, cross-system inspections• How the new inspection actually works — following one thread across the whole quality system• Why readiness is a daily habit, not a pre-inspection scramble• The inspection playbook: war room, back room, document retrieval, SME selection, escort discipline• Making complaints, CAPA, deviations, and risk tell one consistent story• What the investigator asks for first — and what it reveals• The QMSR-era shift: from procedures to effectiveness• The Monday-morning playbook: pull the thread before the investigator doesNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.
- 2 weeks ago13 min
Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained
Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count down the five CAPA effectiveness failures that keep quality teams in warning-letter territory: fixing the event instead of the system, root causes that stop at human error, CAPAs closed with no proof they worked, CAPAs written to answer the 483 instead of fixing the system, and no trending — so the failure recurs.• Why CAPA is the most rejected document in FDA enforcement• Failure one: corrective action with no preventive action — fixing the event, not the system• Failure two: root causes that stop at "human error"• Failure three: closing a CAPA with zero evidence the change worked• Failure four: CAPAs written to answer the 483 observation, not to fix the system• Failure five: no trending — the same failure recurs, and FDA cites recurrence• The Monday-morning CAPA playbook that survives an investigatorNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.
- 2 weeks ago13 min
Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained
Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count down the five CAPA effectiveness failures that keep quality teams in warning-letter territory: fixing the event instead of the system, root causes that stop at human error, CAPAs closed with no proof they worked, CAPAs written to answer the 483 instead of fixing the system, and no trending — so the failure recurs.• Why CAPA is the most rejected document in FDA enforcement• Failure one: corrective action with no preventive action — fixing the event, not the system• Failure two: root causes that stop at "human error"• Failure three: closing a CAPA with zero evidence the change worked• Failure four: CAPAs written to answer the 483 observation, not to fix the system• Failure five: no trending — the same failure recurs, and FDA cites recurrence• The Monday-morning CAPA playbook that survives an investigatorNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.
- 2 weeks ago14 min
OOS Investigation Explained: Phase 1 vs Phase 2 (21 CFR 211.192)
An out-of-specification result lands on your desk — and one wrong decision in the next hour can manufacture the evidence for your own warning letter. Marcus and Priya break down the two-phase OOS investigation step by step: Phase 1, the laboratory investigation, and Phase 2, the full-scale investigation, under 21 CFR 211.192 — from the Barr Labs decision to the retest rules to what to do on Monday morning.• Phase 1 vs Phase 2: what each phase covers and where the line is• The retest rules — when retesting is legitimate and when it's testing into compliance• Why "no assignable lab cause" is a finding, not a failure• What 21 CFR 211.192 actually requires, in plain language• The Monday-morning OOS playbook, in five stepsNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.
- 3 weeks ago14 min
ALCOA+ Explained: The 9 Data Integrity Principles FDA Actually Cites
When an FDA investigator stops trusting your data, the inspection is over — because if the records can't be trusted, nothing built on them can be. Marcus and Priya break down all nine ALCOA+ principles — Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available — what investigators actually find when each one is missing, and the Monday-morning fixes that close most findings before they happen.• The 9 ALCOA+ principles, explained in plain language• What investigators actually check first: audit trails, user access, backups, QA's real role• Why most data integrity 483s are discipline failures, not technology failures• The small-site objection steel-manned: where the money actually matters• The 4 moves a QA manager should make this weekNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.
Get The GMP Insider summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
FDA Watch
A regulatory expert hosts discussions on FDA policies and developments across pharmaceuticals, devices, food, and cosmetics.
In the Interim...
Explores Bayesian statistics and adaptive clinical trial designs in medical research with insights from industry experts.
DR. GUNDRY PODCAST: GUT HEALTH, WEIGHT LOSS, AND NUTRITION
Explores gut health, nutrition, and chronic illness through the lens of plant-based diets, lectin avoidance, and microbiome science.
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
The David Guttman Podcast
Conversations with top leaders on building wealth, integrity, and a meaningful life through real-world lessons and authentic mentorship.
Out of the Gray (Gy) - Standard Imaging
Conversations with experts in radiation oncology exploring advancements in technology, research, and clinical practice.
Sam Miller Science
Sam Miller
The Holistic GLP-1 Podcast with Elizabeth McGann
Explores holistic approaches to GLP-1 for metabolic health, weight, and well-being through expert insights and natural strategies.
The Health Continuum
High-performing professionals learn science-based health strategies to sustain energy, focus, and resilience in demanding careers.
Peak Performance Life Podcast
Covers health, energy, and mental performance optimization through biohacking, nutrition, and lifestyle strategies.
Get Better Faster
Doctors and researchers discuss functional medicine and root-cause approaches to chronic illness and health optimization.
Data & Science with Glen Wright Colopy
Discusses healthcare technology with experts, focusing on data science and engineering innovations in clinical applications.
About The GMP Insider
GMP Insider is your go-to podcast for practical insights into pharmaceutical quality, Good Manufacturing Practices (GMP), and regulatory compliance.Designed for quality professionals, manufacturing teams, and pharma leaders, this show breaks down complex regulations into clear, real-world guidance. Each episode explores topics like audits, CAPA, data integrity, quality systems, validation, and global regulatory expectations — all with a focus on protecting patients and building strong quality cultures.Whether you work in Quality Assurance, Quality Control, Manufacturing, or Regulatory Affairs, GMP Insider helps you stay compliant, confident, and ahead in an ever-evolving pharmaceutical industry.New episodes deliver:• GMP best practices• Audit readiness strategies• Real compliance case studies• Industry trends and updates• Expert tips from quality professionals From batch to patient — quality is everything.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The GMP Insider in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The GMP Insider daily summary?
It's a free AI-powered email that summarizes new episodes of The GMP Insider as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The GMP Insider podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The GMP Insider product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Tushar Arora.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
What topics does The GMP Insider cover?
The GMP Insider covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The GMP Insider summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.